Loading...

SLNO SOLENO THERAPEUTICS INC Disposals and divestitures 8-K Filing

SLN

SLN

SOLENO THERAPEUTICS INC

(SLNO)

2026 8-K

Marketing Withdrawal

Merger Agreement Announced

Bylaw Amendments

Management Change

Financial Results Report

Executive Compensation Update

Financial Results Announcement

Share Buyback Approved

Financial Results Announced

Board Appointment

Adverse Event Report

Investor Roadshow

Financial Statements

Equity Offerings

Financial Statements

Financial Statements

Accountant Change

Financial Results

Executive Compensation

FDA Review Extension

Financial Results

Financial Results Announcement

Sale Agreement with Jefferi...

Stock Grants to Employees

Lease Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering of Common S...

FDA Breakthrough Therapy De...

Amendment to Inducement Equ...

Compensation Increase

Public Offering and Private...

Termination of Sales Agreement

Regulation FD Disclosure

Appointment of Director

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results and Equit...

Completion of Enrollment in...

Financial Results Announcement

Amendment to Inducement Plan

Compensation Increases for ...

External Links:

On April 7, 2026, Soleno Therapeutics Inc. voluntarily withdrew its marketing authorization application for VIOKAT prolonged-release tablets intended for treating Prader-Willi syndrome, based on strategic business considerations. This withdrawal maintains the option for future regulatory engagement.

AI Assistant

SOLENO THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.